Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
Microbot Medical received its first international regulatory approval for the LIBERTY Endovascular Robotic System from Israel's AMAR Division. This clearance allows the company to market and commercialize the system in Israel, serving as the second jurisdiction after the U.S. to approve the device.
Key figures
- Ce mark target
- end of 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.